Anika Therapeutics, Inc. ANIK R2KR3KPHARMA
Company Overview
Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.18.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $112.82M (-5.9% YoY); net profit $-10.88M.
- Trailing 12 Months Year-on-year growth — revenue +15.6%.
- 5-Year Trend Long-term compounding — revenue CAGR 7.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 7.13% |
| 1 Year: | 15.60% |
Stock Price Performance
| 1 Year: | +135.90% |
| 6 Months: | +39.36% |
| 3 Months: | +42.61% |
| 1 Month: | +5.88% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)61.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | ANIK Anika Therapeutics, Inc. R2KR3KPHARMA | 21.42 | -93.13 | $286.66M | 0.00% | -6.56% | -2.19% | 7.13% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | 23.39M | 33.46M | 27.18M | 29.39M | 21.26M | 30.55M | 26.79M | 26.96M | 24.72M | 30.42M | 29.70M | 29.77M | 35.40M | 30.68M | 31.69M | 32.69M | 34.29M | 38.15M | 39.54M | 36.69M | 39.66M | 40.26M | 37.92M | 44.30M | 41.47M | 29.02M | 30.72M | - | 26.17M | 28.22M | 27.82M | 30.61M | 29.61M | 32.61M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 11.49M | 13.86M | 12.23M | 11.44M | 10.62M | - |
| Gross Profit | 18.50M | 19.32M | 16.85M | 20.51M | 20.79M | 20.76M | 17.30M | 22.02M | 20.93M | 20.17M | 13.41M | 22.39M | 18.50M | 19.95M | 17.41M | 23.58M | 23.75M | 21.12M | 21.20M | 13.74M | 17.34M | 16.75M | 20.97M | 20.81M | 23.02M | 21.80M | 24.86M | 22.78M | 22.84M | 28.97M | 24.94M | 18.98M | 20.49M | - | 14.68M | 14.36M | 15.58M | 19.18M | 19.00M | 21.24M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.96M | 18.54M | 18.82M | 18.53M | 24.48M | - |
| Operating Income | 13.13M | - | 10.71M | 13.47M | 13.69M | - | 8.01M | 17.73M | 10.27M | - | -7.83M | 11.25M | 8.57M | - | 5.48M | 11.91M | 12.05M | - | 7.09M | -9.54M | -7.93M | - | 1.26M | 9.18M | 1.30M | -3.55M | -3.38M | -5.80M | -12.55M | -3.63M | -7.67M | -2.50M | -1.81M | - | -4.28M | -4.18M | -3.23M | 646.00K | -5.49M | 2.95M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.69M | -2.76M | -1.83M | 1.96M | -4.08M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -3.87M | -3.97M | -2.24M | 764.00K | -4.82M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 89.00K | 681.00K | 939.00K | -1.04M | 235.00K | - |
| Net Income | 8.38M | 11.04M | 6.89M | 8.62M | 8.95M | 8.09M | 5.49M | 11.37M | 6.89M | 8.07M | -6.69M | 10.09M | 7.60M | 7.72M | 4.51M | 9.44M | 9.20M | 4.05M | 5.79M | -7.71M | -6.41M | -15.66M | 2.84M | 6.53M | 558.00K | -2.93M | -2.84M | -4.17M | -10.35M | -2.74M | -6.58M | -4.51M | -88.00K | - | -4.87M | -3.97M | -2.33M | 292.00K | -5.06M | 3.31M |
| Diluted EPS | 0.55 | 0.72 | 0.45 | 0.57 | 0.59 | 0.54 | 0.37 | 0.76 | 0.46 | 0.53 | -0.46 | 0.68 | 0.53 | 0.54 | 0.31 | 0.67 | 0.66 | 0.28 | 0.40 | -0.54 | -0.45 | -1.10 | 0.20 | 0.45 | 0.04 | -0.20 | -0.20 | -0.29 | -0.71 | -0.19 | -0.45 | -0.31 | 0.00 | - | -0.34 | -0.28 | -0.16 | 0.02 | -0.37 | 0.24 |
| R&D Expense | 2.06M | - | 2.16M | 2.79M | 2.82M | - | 4.23M | 4.45M | 5.84M | - | 5.16M | 4.73M | 4.23M | - | 4.26M | 4.17M | 4.16M | - | 6.05M | 4.53M | 5.22M | - | 6.36M | 7.29M | 7.67M | 6.16M | 6.97M | 7.30M | 8.40M | 8.91M | 7.79M | 6.41M | 6.68M | 5.95M | 6.06M | 6.31M | 6.95M | - | 6.71M | 7.34M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.14M | 55.56M | 64.78M | 71.36M | 75.08M | 105.59M | 93.00M | 103.38M | 113.42M | 105.56M | 114.61M | 130.46M | - | 113.83M | 120.79M | 119.91M | 112.82M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | 40.61M | 38.26M | 43.91M | 49.01M |
| Gross Profit | - | - | - | - | - | - | - | - | - | 74.28M | 85.86M | 69.03M | - | 73.22M | 82.53M | 76.00M | 63.81M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | 69.55M | 81.69M | 81.10M | 74.86M |
| Operating Income | 5.59M | 7.54M | 13.97M | 19.72M | 32.61M | 61.45M | 48.13M | 50.61M | 45.73M | 21.75M | 34.25M | -28.32M | - | 3.67M | 844.00K | -5.10M | -11.05M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.16M | 15.06M | 3.02M | -5.32M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.32M | 3.16M | -2.76M | -9.31M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.12M | 6.59M | 6.06M | 672.00K |
| Net Income | 3.69M | 4.32M | 8.47M | 11.76M | 20.57M | 38.32M | 30.76M | 32.55M | 31.82M | 18.72M | 27.19M | -23.98M | - | -14.86M | -82.67M | -56.38M | -10.88M |
| Diluted EPS | 0.32 | 0.32 | 0.62 | 0.82 | 1.39 | 2.51 | 2.01 | 2.15 | 2.11 | 1.27 | 1.89 | -1.69 | - | -1.02 | -5.64 | -3.83 | -0.76 |
| R&D Expense | 8.18M | 6.87M | 6.17M | 5.39M | 7.06M | 8.14M | 8.99M | 10.73M | 18.79M | 18.19M | 16.66M | 23.43M | 27.33M | 18.32M | 21.76M | 25.54M | 25.77M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 128.94M | 132.84M | 142.07M | 156.04M | 192.81M | 235.75M | 240.25M | 282.62M | 278.99M | 330.71M | 365.61M | - | 349.13M | 270.63M | 202.74M | 190.27M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 169.55M | 163.31M | 113.65M | 103.36M |
| Cash & Equivalents | 43.19M | 24.43M | 28.20M | 35.78M | 44.07M | 63.33M | 100.16M | 110.71M | 104.26M | 133.26M | 89.04M | 157.46M | 95.82M | - | 86.33M | 68.74M | 55.63M | 57.48M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 39.77M | 24.43M | 23.81M | 18.79M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 34.63M | 26.36M | 23.59M | 23.69M |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 63.56M | 58.37M | 48.75M | 46.80M |
| Current Liabilities | - | - | 19.37M | 14.54M | 14.45M | 9.28M | 5.97M | 17.28M | 8.80M | 13.07M | 11.29M | 16.28M | 36.87M | - | 27.91M | 31.06M | 23.31M | 21.91M |
| Long Term Debt | - | - | 11.20M | 9.60M | 8.00M | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 30.89M | 27.74M | 25.93M | 26.25M |
| Total Equity | 60.76M | 82.14M | 85.19M | 94.76M | 108.92M | 135.63M | 178.10M | 210.85M | 222.77M | 263.49M | 263.61M | 288.38M | 272.40M | - | 285.56M | 212.26M | 153.99M | 143.47M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 14.62M | 14.85M | 15.01M | 15.38M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.09M | 7.85M | 10.17M | 10.55M | 25.16M | 39.98M | 39.91M | 24.45M | 40.81M | 34.92M | 37.01M | 13.06M | - | 4.41M | -1.79M | 5.40M | 11.19M |
| Investing Cash Flow | -20.22M | -2.68M | -1.40M | -1.50M | -253.00K | -8.30M | -30.23M | -6.76M | -12.48M | -50.26M | 39.69M | -71.26M | - | -7.49M | -5.43M | -8.33M | -401.00K |
| Financing Cash Flow | -1.64M | -1.34M | -1.17M | -758.85K | -5.69M | 5.33M | 1.07M | -23.99M | 314.00K | -28.90M | -8.14M | -3.77M | - | -4.85M | -6.32M | -12.73M | -10.55M |
| Capital Expenditure | -3.96M | -2.78M | -1.40M | -1.50M | -441.00K | -1.55M | -9.22M | -14.01M | -8.98M | -4.66M | -2.83M | -1.63M | - | -7.49M | -5.43M | -8.33M | -6.83M |
| Free Cash Flow | -867.53K | 5.07M | 8.77M | 9.04M | 24.72M | 38.42M | 30.69M | 10.43M | 31.83M | 30.26M | 34.18M | 11.44M | - | -3.08M | -7.21M | -2.93M | 4.36M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | -7.93M | -13.54M | -15.66M | 236.00K |
| Share Buybacks | - | - | - | - | - | - | - | 25.00M | - | 30.00M | 30.00M | 0 | 0 | 0 | 5.00M | 10.91M | 9.48M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 70.4% | 74.9% | 52.9% | - | 64.3% | 68.3% | 63.4% | 56.6% |
| Operating Margin % | 13.9% | 13.6% | 21.6% | 27.6% | 43.4% | 58.2% | 51.8% | 49.0% | 40.3% | 20.6% | 29.9% | -21.7% | - | 3.2% | 0.7% | -4.3% | -9.8% |
| Net Margin % | 9.2% | 7.8% | 13.1% | 16.5% | 27.4% | 36.3% | 33.1% | 31.5% | 28.1% | 17.7% | 23.7% | -18.4% | - | -13.1% | -68.4% | -47.0% | -9.6% |
| ROE % | 4.5% | 5.1% | 8.9% | 10.8% | 15.2% | 21.5% | 14.6% | 14.6% | 12.1% | 7.1% | 9.4% | -8.8% | - | -5.2% | -38.9% | -36.6% | -7.6% |
| ROCE % | - | 6.9% | 11.8% | 15.4% | 22.2% | 32.9% | 22.0% | 21.9% | 17.0% | 8.1% | 10.9% | -8.6% | - | 1.1% | 0.4% | -2.8% | -6.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 10.83% | 1.45M | $28.38M |
| 2 | Caligan Partners, LP | 10.72% | 1.44M | $28.10M |
| 3 | Morgan Stanley | 4.59% | 614.32K | $12.03M |
| 4 | Acadian Asset Management. LLC | 4.53% | 606.54K | $11.88M |
| 5 | Vanguard Capital Management LLC | 4.27% | 572.11K | $11.20M |
| 6 | AQR Capital Management, LLC | 4.18% | 559.85K | $10.96M |
| 7 | Boothbay Fund Management, LLC | 3.96% | 529.64K | $10.37M |
| 8 | Renaissance Technologies, LLC | 3.60% | 481.42K | $9.43M |
| 9 | Dimensional Fund Advisors LP | 3.37% | 451.10K | $8.83M |
| 10 | Capital Management Corporation | 3.35% | 448.47K | $8.78M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ANIK
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
BEDFORD, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2026 financial results be…
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
Here is how Anika Therapeutics (ANIK) and Concentra Group (CON) have performed compared to their sector so far this year.
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.
NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.
ANIK — Frequently Asked Questions
What is the current share price of Anika Therapeutics, Inc. (ANIK)?
As of 2026-10-23 16:27 PDT, Anika Therapeutics, Inc. (ANIK) trades at $21.42 on NasdaqGS. Its 52-week range is $8.37 to $22.03.
What is the market capitalisation of ANIK?
Anika Therapeutics, Inc. (ANIK) has a market capitalisation of $286.66M on NasdaqGS.
What is the P/E ratio of ANIK?
ANIK trades at a trailing price-to-earnings (P/E) ratio of -93.13. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 1.91.
What is the return on equity (ROE) of ANIK?
ANIK has a return on equity (ROE) of -2.19%. Its return on capital employed (ROCE) is -6.56%.
Is ANIK a good stock to buy?
This page provides a data-driven analysis of Anika Therapeutics, Inc. (ANIK), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.